Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027651 (tumor)
685,946 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In a previous study, we demonstrated that supernatants from human T cell clones stimulated by a pair of anti-CD2 monoclonal antibodies cause resting human B cells to become activated and to proliferate in the absence of any other signals. The activity responsible for these effects was shown to be different from already characterized lymphokines and in particular from IL-2 and IL-4, and was named B Cell Activating Factor or BCAF. In this paper, we describe the production of BCAF by a human T cell tumor line T687 after phorbol myristate acetate (PMA) stimulation; this production can be potentiated by phytohemagglutinin (PHA). We further show that the stimulatory phase can be separated from the secretory phase thereby avoiding contamination of BCAF-containing supernatant by PMA and PHA. Supernatants produced under these conditions do not contain either IL-4 or IFN but contain traces of lymphotoxin and 2 to 10 ng/ml of IL-2. The T687 cell line will allow us to obtain a large volume of supernatant for biochemical study and purification of the molecule(s) responsible for BCAF activity.
...
PMID:Human B cell activating factor (BCAF): production by a human T cell tumor line. 249 79

The exposure of experimental animals to the inflammatory effects of ultraviolet radiation (UVR) is known to cause depressions in their ability to initiate and effectuate various types of cellular immune responses. Contact-type and delayed-type hypersensitivity, plus the ability to generate protective forms of anti-viral and anti-tumor immunity, are all affected by the prior exposure of normal animals to the effects of this physical agent. Presently, the cellular and molecular mechanism(s) responsible for mediating the changes in immune function observed in UVR-exposed animals is not fully understood. Herein we report that one reproducible consequence of exposing normal mice to low doses of UVR is a dramatic change in the pattern of lymphokines secreted by their activated T cells. Lymphocytes isolated from UVR-exposed donors produce/secrete greatly reduced levels of the T cell lymphokines IL-2 and IFN-gamma activation in vitro with protein Ag of the polyclonal T cell stimulant anti-CD3. The secretion of IL-4 by these lymphocyte cultures, however, is consistently elevated in comparison to normal controls. Further studies determined that a similar change in lymphokine production was induced when mice were treated with either bacterial LPS or rIL-1 beta, a cytokine known to be elevated in vivo after UVR or LPS exposure. The ability of IL-1 to facilitate a change in the capacity of T lymphocytes to produce/secrete lymphokines after in vitro activation does not appear to represent a direct effect of this cytokine on lymphocyte or accessory cell targets because addition of IL-1 beta to cultures of Ag-primed lymphocytes obtained from normal donors was incapable of altering the pattern of lymphokine production. Collectively, our present results add further support to the hypothesis that UVR-induced elevations in endogenous IL-1 are, in part, responsible for the immunomodulatory effects of UVR. These findings provide compelling evidence that UVR, plus other agents capable of endogenously stimulating the production of IL-1, may function to alter the expression of different effector mechanisms in vivo. This could be facilitated through selective reductions in lymphokines produced by Th-1-type cells (IL-2 and IFN-gamma) and a simultaneous augmentation in a lymphokine produced by Th-2-type cells (IL-4).
...
PMID:Regulation of murine lymphokine production in vivo. Ultraviolet radiation exposure depresses IL-2 and enhances IL-4 production by T cells through an IL-1-dependent mechanism. 250 68

Macrophages exert important roles in the host defense mechanism, such as antigen presentation and destructions of tumor cells. Analysis of macrophage functions as effector cells in the tumor cell destruction has been carried out mainly from two aspects. One is the macrophage activation, during which macrophages are sequentially activated from resting cells to fully activated cells with capability to destroy tumor cells. The other is analysis of active moieties which mediate macrophage tumoricidal activity. The recombinant cytokines become available, and IFN-gamma has been found to be a major constituent of macrophage activating factor. It has been also reported that TNF, -IL-4, GM-CSF or IL-2 has MAF activity. The precise mechanism of signal transduction of IFN gamma will be defined by the recent progress on IFN gamma receptor purification and gene cloning for IFN gamma receptor as well as on the analysis of IFN gamma-inducible genes. As the mechanism of macrophage-mediated tumoricidal activity, two pathways, TNF-dependent and arginine-dependent ones, have been proposed.
...
PMID:[Mechanisms of macrophage activation and macrophage-mediated tumoricidal activity]. 250 64

This report initially reviews the progressive steps of research designed to build up a new, well-defined helper system triggering both the non-specific and the tumor-specific immune reactivity of a host bearing a tumor, in order to impair tumor growth. Tumor-specific T-helper lymphocytes were first generated in vitro from the spleen of mice with evident tumors. As these lymphocytes inhibit tumor growth by recruiting host reactivity through the release of lymphokines, the peri-tumoral injection of interleukin-2 (IL-2) was then experimented. Repeated injections of 10 units of IL-2 are only weakly effective, but its triggering of an efficient anti-tumor reactivity is markedly enhanced when non-reactive lymphocytes directly obtained from tumor-bearing mice are artificially admixed with the challenge tumor cells. Lastly, in order to ascertain whether lymphocytes themselves could be dispensed with, lymphokines were injected around tumor-draining lymph nodes. Ten daily injections of 1 pg of the 163-171 synthetic nonapeptide of human IL-1 beta appeared very efficient in activating tumor inhibition, particularly when combined with IL-4 or (to a lesser extent) IL-2.
...
PMID:Lymphokine-activated tumor inhibition: combinatory activity of a synthetic nonapeptide from interleukin-1, interleukin-2, interleukin-4, and interferon-gamma injected around tumor-draining lymph nodes. 250 86

When cultured with IL-2, human lymphoid cells acquire the ability to lyse various NK-resistant tumor targets. Due to their anti-tumor cytolytic effect, clinical trials with IL-2 alone or IL-2 + IL-2-activated killer (IAK) lymphocytes have been undertaken. However, infusion of therapeutically effective doses of IL-2 is associated with the development of systemic toxicity characterized by exaggerated endothelial permeability, also known as vascular leak syndrome. The present study was designed to examine the effects of IAK cells and their secreted products on vascular endothelial permeability by using an in vitro endothelial permeability model in which the flux of FITC-albumin across endothelial cell (EC) monolayers was measured. When endothelial monolayers were exposed to IAK cells for 2 h, significant increases in the transendothelial permeability to albumin were observed. Exposure of EC to lymphocytes cultured in the absence of IL-2 did not induce significant alteration in the endothelial permeability. In addition, neither culture supernatants of IAK cells nor purified recombinant cytokines, including IL-1 beta, IL-2, IL-3, IL-4, IL-6, TNF-alpha, GM-CSF, M-CSF, and IFN-gamma, had any effect on endothelial permeability in this model. Prior activation of EC with TNF-alpha did not alter the increased permeability induced by IAK cells or lack of it by nonactivated lymphocytes. Dexamethasone treatment of IAK cells abolished their anti-tumor cytolytic effect but only partially inhibited their ability to induce increased endothelial permeability. Pretreatment of IAK cells with mAb directed at the CD11a/CD18 (LFA-1) adhesion complex, and that of EC with mAb directed at the ICAM-1 molecule, inhibited the IAK cell-induced increase in endothelial permeability. These results demonstrate that direct cell-to-cell contact between IAK cells and EC is necessary and sufficient to cause increased endothelial permeability in this model system, and may therefore be an important factor contributing to the development of the vascular leak syndrome observed clinically.
...
PMID:IL-2-activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers. Implications for vascular leak syndrome. 252 65

The present study examines the effects of IL-4 and TNF-alpha on the CD3-dependent (Ag/MHC-initiated or anti-CD3 mAb-initiated) and CD3-independent (IL-2-initiated) pathways of the initiation of human T-cell activation. Both IL-4 and TNF-alpha significantly augmented the CD3-dependent T-cell proliferation induced by either irradiated OKT3 hybridoma cells or allogeneic B cells. In contrast, the CD3-independent IL-2-initiated T-cell proliferation was enhanced by TNF-alpha and significantly inhibited by IL-4. Although the growth-enhancing effects of both IL-4 and TNF-alpha on the CD3-dependent T-cell proliferation were noticeable regardless of when these cytokines were introduced in culture, the inhibitory effect of IL-4 on the CD3-independent IL-2-initiated T-cell activation was observed only if IL-4 was added at the initiation but not later than 24 hr of "T cells + IL-2" cultures. The growth-enhancing effects of both IL-4 and TNF-alpha on the CD3-dependent T-cell activation were not confined to any one subset of T cells. On the other hand, IL-4 inhibited the IL-2-induced proliferation of CD4+ (helper/inducer) T cells and CD45R+ (virgin) T cells but not that of CD8+ (cytotoxic/suppressor) T cells and CD45R (memory) T cells. When examined for their effects on cytokine production, CD3-dependent production of IL-2 and IFN-gamma was affected by neither cytokine, whereas IL-4 strongly inhibited the production of IFN-gamma by IL-2-stimulated T cells. Consistent with their enhancing and inhibitory effects, respectively, on IL-2-induced T-cell proliferation, TNF-alpha augmented and IL-4 inhibited the development of IL-2-stimulated MHC-unrestricted cytolytic (MUC) T-cell activity directed against tumor cells. When deprived of IL-2, MUC T cells rapidly lose their cytolytic activity, and despite its inhibitory effect on the development of MUC T cells, exposure of IL-2-deprived MUC T cells with decaying cytolytic activity to IL-4 retards the decay in their cytolytic activity. These results suggest the differential regulatory effects of IL-4 and TNF-alpha during human T-cell activation.
...
PMID:Distinct regulatory effects of IL-4 and TNF-alpha during CD3-dependent and CD3-independent initiation of human T-cell activation. 252 10

Thymus-derived lymphocytes (T cells) are thought to play an important role in the recognition and destruction of neoplastic cells in the host. This principle has provided a foundation for the establishment of therapy with T-cell-stimulating lymphokines, notably interleukin-2, as an approach to the eradication of certain malignancies. Another lymphokine, B-cell-stimulatory factor-1 (BSF-1), also known as IL-4, has also been shown to be capable of inducing T-cell proliferation and cytolytic activity in vitro. We demonstrate herein that in immunosuppressed mice, in vivo IL-4 administration enhances the ability of treated animals to generate cytotoxic T lymphocytes directed against an allogeneic tumor challenge. Moreover, IL-4 is approximately 25 times more effective, on a weight basis, than is IL-2 in augmenting cytotoxic T-lymphocyte activity. This difference in efficiency between the two lymphokines may be partly due to the in vivo half-life. We have found that IL-4 has a serum half-life of 19 +/- 2 min following intravenous administration, in contrast to the half-life of IL-2, which has been reported to be 3.7 min +/- 0.8. These results are not only of interest for our basic understanding of the physiological role of IL-4 but may have immediate importance in clinical settings where lymphokine therapy is contemplated.
...
PMID:Interleukin-4 (B-cell stimulatory factor-1) augments the in vivo generation of cytotoxic cells in immunosuppressed animals. 256 42

Proliferation in vitro of the in vivo passaged murine B cell tumor line BCL1 has been used as a standard assay for mouse interleukin-5 (IL-5) for a number of years. We demonstrate that this line will also respond to human IL-5. The response to murine IL-5 is abrogated by transforming growth factor-beta and to a lesser extent by interferon-gamma. This suggests a possible regulatory role for these lymphokines in the proliferation of B cells induced by IL-5. Other purified recombinant lymphokines were also tested for their ability to induce BCL1 proliferation. The lymphokines IL-1, IL-2, IL-3, and IL-6 had no effect on the growth of BCL1. In contrast, IL-4 and more surprisingly granulocyte-macrophage colony-stimulating factor (GM-CSF) also induced proliferation of this cell. These effects could be inhibited by specific antibodies directed against the respective lymphokines. These data suggest that GM-CSF, as well as IL-4 and IL-5, may be yet another regulator of neoplastic and possibly even normal B-cell growth and differentiation.
...
PMID:The BCL1 B lymphoma responds to IL-4, IL-5, and GM-CSF. 267 47

PGM-1 is a transplantable leukemia of C3H/HeJ mice growing as a population of undifferentiated blast cells with a predisposition to form subcutaneous tumors and to grow in lymphoid organs. Cell survival and proliferation in vitro are absolutely dependent on stimulation by hemopoietic growth factors, and up to 100% of tumor cells can form colonies of mature granulocytes and/or macrophages in semisolid cultures, the colonies containing no clonogenic cells. Most clonogenic cells in the leukemic population respond to stimulation by multi-colony-stimulating factor (IL-3) or GM-CSF, but some respond also to M-CSF, G-CSF, IL-4, IL-5, or IL-6. In their surface phenotype and proliferative characteristics in vitro, PGM-1 leukemic cells resemble normal granulocyte-macrophage progenitor cells, and the leukemia may be a useful model for human chronic myeloid leukemia.
...
PMID:PGM-1: a transplantable murine leukemia of granulocyte-macrophage progenitor cells. 268 46

Macrophage activation factor (MAF) activity, assessed by the ability to activate macrophages (MO) to lyse RBL--a TNF-resistant, retrovirally transformed, tumor target--was detected in the PHA-stimulated supernatant (Sup) of LBRM, a murine T cell line. LBRM Sup provided a priming signal to MO, but required the subsequent addition of small amounts of LPS for the expression of tumor cytotoxicity. The identity of the lymphokine responsible for this MAF activity was investigated. IFN-gamma, the only previously characterized lymphokine capable of priming MO for tumor cytotoxicity, did have MAF activity in the assay, but IFN-gamma could not be detected by ELISA in LBRM Sup, and LBRM-derived mRNA lacked detectable message for IFN-gamma. Moreover, anti-IFN-gamma failed to inhibit the MAF activity of LBRM Sup, suggesting that the presence of small, undetectable amounts of IFN-gamma were neither responsible nor required for LBRM MAF activity. LBRM MAF activity appeared distinct from the other previously identified lymphokines produced by LBRM, since granulocyte-macrophage-CSF, IL-2, and IL-3 purified from LBRM Sup were unable to activate MO to lyse RBL. IL-4 and TNF, two lymphokines not known to be produced by LBRM but able to activate MO for cytotoxicity of some tumor targets, were also unable to activate MO for RBL cytotoxicity. LBRM MAF lacked antiviral activity in biologic assays, further distinguishing the lymphokine from IFN-gamma, and had an apparent Mr of 30,000 Da using gel filtration chromatography. Thus, the LBRM T cell line produces a previously undescribed lymphokine that primes MO for tumor cytotoxicity.
...
PMID:Identification of a unique T cell-derived lymphokine that primes macrophages for tumor cytotoxicity. 268 79


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>